• FirefoxInstall the new Firefox »
  •  Dow Down0.23% Nasdaq Down0.27%

    Halozyme Therapeutics, Inc. (HALO)

    -NasdaqGS
    13.31 Up 0.02(0.15%) Mar 26, 4:00PM EDT
    |After Hours : 13.31 0.00 (0.00%) Mar 26, 4:37PM EDT
    Add to Portfolio
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingDec 31, 2014Sep 30, 2014Jun 30, 2014Mar 31, 2014
    Total Revenue 30,377   14,606   18,385   11,966  
    Cost of Revenue6,147  5,141  5,924  5,520  
    Gross Profit 24,230   9,465   12,461   6,446  
    Operating Expenses
    Research Development19,728  19,904  18,649  21,415  
    Selling General and Administrative8,353  8,587  8,752  10,250  
    Non Recurring -   -   -   -  
    Others -   -   -   -  
    Total Operating Expenses -   -   -   -  
    Operating Income or Loss (3,851) (19,026) (14,940) (25,219)
    Income from Continuing Operations
    Total Other Income/Expenses Net(45)122  118  47  
    Earnings Before Interest And Taxes(3,896)(18,904)(14,822)(25,172)
    Interest Expense1,378  1,376  1,451  1,376  
    Income Before Tax(5,274)(20,280)(16,273)(26,548)
    Income Tax Expense -   -   -   -  
    Minority Interest -   -   -   -  
    Net Income From Continuing Ops(5,274)(20,280)(16,273)(26,548)
    Non-recurring Events
    Discontinued Operations -   -   -   -  
    Extraordinary Items -   -   -   -  
    Effect Of Accounting Changes -   -   -   -  
    Other Items -   -   -   -  
    Net Income (5,274) (20,280) (16,273) (26,548)
    Preferred Stock And Other Adjustments -   -   -   -  
    Net Income Applicable To Common Shares (5,274) (20,280) (16,273) (26,548)

    Sign Up for a Free Trial to EDGAR Online Premium!
    Get the critical business and financial information you need for more than 15,000 U.S. public companies.
    Sign Up Now - Learn More

    Currency in USD.